Royalty Pharma plc — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
On 11 August 2026, Royalty Pharma plc amended and restated its Exchange Agreement (originally dated 16 June 2020, previously amended 29 Dec 2023, 31 Dec 2024, 16 May 2025). The amendment removes three international entities—RPI International Holdings 2019, LP; RPI International Partners 2019, LP; and RPI International Feeder 2019, LP—as parties after they ceased holding Holdings B DRs and were liquidated. All obligations and liabilities of these entities are terminated and released. The restated agreement governs exchanges of Holdings B DRs, Direct B DRs, and EPA B DRs for Parent A Shares at a 1:1 initial exchange rate, with mechanics unchanged materially.
Why this rating
Routine corporate restructuring. Removal of dormant entities post-liquidation is administrative. No material financial impact, no change to operational economics or shareholder rights; immaterial relative to $16.7B market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.